Peter L Roberson1, Lauren B Smith2, Meredith A Morgan1, Matthew J Schipper1, Scott J Wilderman3, Anca M Avram3, Mark S Kaminski4, Yuni K Dewaraja3. 1. 1 Department of Radiation Oncology, University of Michigan , Ann Arbor, Michigan. 2. 2 Department of Pathology, University of Michigan , Ann Arbor, Michigan. 3. 3 Department of Radiology, University of Michigan , Ann Arbor, Michigan. 4. 4 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan , Ann Arbor, Michigan.
Abstract
INTRODUCTION: Non-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction. MATERIALS AND METHODS: Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient. RESULTS: Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone. CONCLUSIONS: It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.
INTRODUCTION:Non-Hodgkin Lymphomapatients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction. MATERIALS AND METHODS: Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient. RESULTS: Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone. CONCLUSIONS: It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.
Authors: Anant Narayan Bhatt; Rohit Mathur; Abdullah Farooque; Amit Verma; B S Dwarakanath Journal: Indian J Med Res Date: 2010-08 Impact factor: 2.375
Authors: George Sgouros; Shannon Squeri; Ase M Ballangrud; Katherine S Kolbert; Jerrold B Teitcher; Katherine S Panageas; Ronald D Finn; Chaitanya R Divgi; Steven M Larson; Andrew D Zelenetz Journal: J Nucl Med Date: 2003-02 Impact factor: 10.057
Authors: R Villuendas; M A Piris; J L Orradre; M Mollejo; P Algara; L Sanchez; J C Martinez; P Martinez Journal: J Pathol Date: 1992-03 Impact factor: 7.996
Authors: Peter L Roberson; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja Journal: Cancer Biother Radiopharm Date: 2013-10-08 Impact factor: 3.099
Authors: Amy Sun; Wei Zhou; Jared Lunceford; Peter Strack; Lisa M Dauffenbach; Christopher A Kerfoot Journal: BMJ Open Date: 2012-10-12 Impact factor: 2.692